{"a": [["Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double\u2010blinded controlled trial", "2014"], ["Novel collagen/gelatin scaffold with sustained release of basic fibroblast growth factor: clinical trial for chronic skin ulcers", "2013 Part A"], ["Efficacy of topical application of beta urogastrone (recombinant human epidermal growth factor) in Wagner's Grade 1 and 2 diabetic foot ulcers: Comparative analysis of 50 patients", "2014"], ["The treatment of diabetic neuropathic foot ulcers with biosynthetic platelet derived growth factor", "1992"], ["Efficacy and Safety Study of DERMAGEN\u00ae vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer", "1937"], ["A Dose Finding Study of Topically Applied I\u2010020201 as an Adjunct to Good Standard\u2010of\u2010care in Patients With Chronic Diabetic Foot Ulcers (DFU)", "2020"], ["The North\u2010West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community\u2010based patient cohort", "2002"], ["Cost\u2010effective management of recalcitrant diabetic foot ulcers", "2002"], ["The personal cost of diabetic foot disease in the developing world \u2010 a study from Pakistan", "2008"], ["Growth factors and the management of the diabetic foot", "2005"], ["Technology evaluation: rh lactoferrin, Agennix", "2004"], ["Quality of life in healing diabetic wounds: does the end justify the means?", "2008"], ["Cost of diabetes\u2010related amputations in minorities", "1998"], ["The development of global consensus guidelines on the management and prevention of the diabetic foot 2011", "2012"], ["Practical guidelines on the management and prevention of the diabetic foot 2011", "2012"], ["GRADE guidelines: 3. Rating the quality of evidence", "2011"], ["Growth factors and cytokines in wound healing", "2008"], ["Reducing the incidence of foot ulceration and amputation in diabetes", "2004"], ["Methodological standards and patient\u2010centeredness in comparative effectiveness research: the PCORI perspective", "2012"], ["A new wound\u2010based severity score for diabetic foot ulcers: a prospective analysis of 1,000 patients", "2006"], ["Growth factors in the treatment of diabetic foot ulcers", "2003"], ["Platelet alpha\u2010granules: basic biology and clinical correlates", "2009"], ["The global burden of diabetic foot disease", "2005"], ["The diabetic foot: grand overview, epidemiology and pathogenesis", "2008"], ["Quality of life with diabetes\u2010associated foot complications: comparison between lower\u2010limb amputation and chronic foot ulceration", "2008"], ["The importance of growth factors for the treatment of chronic wounds in the case of diabetic foot ulcers", "2010"], ["Actovegin(R): a biological drug for more than 5 decades", "2011"], ["SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials", "2013"], ["Microvascular dysfunction in diabetic foot disease and ulceration", "2009"], ["Standardising outcomes for clinical trials and systematic reviews", "2007"], ["Comprehensive Meta\u2010Analysis Sofware", "2011"], ["Granulocyte\u2010colony stimulating factors as adjunctive therapy for diabetic foot infections", "2009"], ["Basic science of wound healing", "2008"], ["Regranex (becaplermin) Gel", "2008"], ["Mechanisms of disease: the oxidative stress theory of diabetic neuropathy", "2008"], ["Platelet\u2010rich plasma: from basic science to clinical applications", "2009"], ["Getting the methods right \u2010 the foundation of patient\u2010centered outcomes research", "2012"], ["Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers", "2006"], ["An economic evaluation of the cost of diabetic foot ulcers: results of a retrospective study on 239 patients", "2003"], ["Quality of life of adults with unhealed and healed diabetic foot ulcers", "2006"], ["Wound healing: the role of growth factors", "2003"], ["GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology", "2011"], ["GRADE guidelines: 1. Introduction \u2010 GRADE evidence profiles and summary of findings tables", "2011"], ["GRADE guidelines: 2. Framing the question and deciding on important outcomes", "2011"], ["GRADE guidelines: 4. Rating the quality of evidence \u2010 study limitations (risk of bias)", "2011"], ["GRADE guidelines: 5. Rating the quality of evidence \u2010 publication bias", "2011"], ["GRADE guidelines 6. Rating the quality of evidence \u2010 imprecision", "2011"], ["GRADE guidelines: 7. Rating the quality of evidence \u2010 inconsistency", "2011"], ["GRADE guidelines: 8. Rating the quality of evidence \u2010 indirectness", "2011"], ["GRADE guidelines: 9. Rating up the quality of evidence", "2011"], ["GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes", "2013"], ["Cost\u2010effectiveness analysis of medical intervention in patients with early detection of diabetic foot in a tertiary care hospital in Bangladesh", "2010"], ["A systematic review on the impact of leg ulceration on patients' quality of life", "2007"], ["Measuring inconsistency in meta\u2010analyses", "2003"], ["A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes", "2008"], ["What is meant by intention to treat analysis? Survey of published randomised controlled trials", "1999"], ["Diabetes and nontraumatic lower extremity amputations. Incidence, risk factors, and prevention \u2010 a 12\u2010year follow\u2010up study in Nauru", "1996"], ["International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR &amp; ICH Guidelines", "1997"], ["The association between baseline characteristics and the outcome of foot lesions in a UK population with diabetes", "2007"], ["Use of the SINBAD classification system and score in comparing outcome of foot ulcer management on three continents", "2008"], ["Better reporting of harms in randomized trials: an extension of the CONSORT statement", "2004"], ["Meta\u2010research: the art of getting it wrong", "2010"], ["History of and factors associated with diabetic foot ulcers in Norway: the Nord\u2010Tr\u00f8ndelag Health Study", "2008"], ["Mortality of first\u2010time amputees in diabetics: a 10\u2010year observation", "2009"], ["Diabetic Foot Ulcers", "2003"], ["Amputation as a marker of the quality of foot care in diabetes", "2004"], ["The incidence of amputation in diabetes", "2005"], ["Re\u2010amputation occurrence in the diabetic population in South Wales, UK", "2007"], ["'Loss of self': a psychosocial study of the quality of life of adults with diabetic foot ulceration", "2003"], ["The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews", "2010"], ["Growth factors in clinical practice", "2000"], ["Platelet\u2010rich plasma: support for its use in wound healing", "2010"], ["Analysis of patient cost for recombinant human platelet\u2010derived growth factor therapy as the first\u2010line treatment of the insured patient with a diabetic foot ulcer", "2009"], ["Classification of diabetic foot wounds", "1996"], ["Reevaluating the way we classify the diabetic foot: restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot", "2008"], ["Risk factors for developing osteomyelitis in patients with diabetic foot wounds", "2009"], ["Lower\u2010extremity amputation. Incidence, risk factors, and mortality in the Oklahoma Indian Diabetes Study", "1993"], ["Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011). The Cochrane Collaboration, 2011", "2011"], ["Risk factors predicting lower extremity amputations in patients with NIDDM", "1996"], ["Factors associated with diabetic patients at high risk for foot ulceration", "2005"], ["Diagnosis and treatment of diabetic foot infections", "2004"], ["'Time is of the essence'. PCORI moves to implement comparative effectiveness research, funding", "2012"], ["Disability and quality of life in Canadian aboriginal and non\u2010aboriginal diabetic lower\u2010extremity amputees", "2005"], ["Diabetic foot: evaluation of evolution and hospital cost of hospitalized patients in Conjunto Hospitalar de Sorocaba", "2001"], ["CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials", "2010"], ["Long\u2010term incidence of lower\u2010extremity amputations in a diabetic population", "1996"], ["Health\u2010related quality of life of diabetic foot ulcer patients and their caregivers", "2005"], ["Lower\u2010extremity amputations in NIDDM. 12\u2010year follow\u2010up study in Pima Indians", "1988"], ["Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration", "2000"], ["The effects of ulcer size and site, patient\u2019s age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers", "2001"], ["Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?", "2007"], ["Becaplermin gel in the treatment of diabetic neuropathic foot ulcers", "2008"], ["Benefit\u2010risk assessment of becaplermin in the treatment of diabetic foot ulcers", "2010"], ["Preliminary draft methodology report: 'Our questions, our decisions: Standards for patient\u2010centered outcomes research'", "2012"], ["A Dictionary of Epidemiology", "2008"], ["Inflammation and neuropeptides: the connection in diabetic wound healing", "2009"], ["The diabetic foot: quality of life", "2004"], ["Reduced vascular endothelial growth factor expression and intra\u2010epidermal nerve fiber loss in human diabetic neuropathy", "2008"], ["Incidence, outcomes, and cost of foot ulcers in patients with diabetes", "1999"], ["The diabetic foot", "2007"], ["Diabetic foot ulcers and amputations: estimates of health utility for use in cost\u2010effectiveness analyses of new treatments", "2004"], ["A longitudinal study of patients with diabetes and foot ulcers and their health\u2010related quality of life: wound healing and quality\u2010of\u2010life changes", "2008"], ["Epidemiology of diabetic foot problems", "2008"], ["Identifying diabetic patients at high risk for lower\u2010extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteria", "1992"], ["Use of platelet growth factors in treating wounds and soft\u2010tissue injuries", "2007"], ["Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies", "2004"], ["Reducing lower leg amputations in diabetes: a challenge for patients, healthcare providers and the healthcare system", "2012"], ["Diagnosis and treatment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress report of the International Working Group on the Diabetic Foot", "2012"], ["CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials", "2010"], ["The Patient\u2010Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda", "2012"], ["Percent change in wound area of diabetic foot ulcers over a 4\u2010week period is a robust predictor of complete healing in a 12\u2010week prospective trial", "2006"], ["The biology of chronic foot ulcers in persons with diabetes", "2008"], ["Search filters", "2010"], ["The cost of diabetic foot conditions", "2007"], ["Risk factors for ipsilateral reamputation in patients with diabetic foot lesions", "2009"], ["The cost of managing diabetic foot ulceration in an Irish hospital", "2004"], ["Platelet functions beyond hemostasis", "2009"], ["Recommendations for examining and interpreting funnel plot asymmetry in meta\u2010analyses of randomised controlled trials", "2011"], ["Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction", "2009"], ["Quality of life and clinical correlates in patients with diabetic foot ulcers", "2005"], ["Cost and resource utilization for prevention and treatment of foot lesions in a diabetic foot clinic in Belgium", "2000"], ["Amputations and ulceration; pitfalls in assessing incidence", "2008"], ["The risk of foot ulceration in diabetic patients with high foot pressure: a prospective study", "1992"], ["Profile of diabetic foot complications and its associated complications \u2010 a multicentric study from India", "2005"], ["The dysvascular foot: a system of diagnosis and treatment", "1981"], ["The therapeutic potential of lactoferrin", "2003"], ["Clinical efficacy of becaplermin (rhPDGF\u2010BB) gel. Becaplermin Gel Studies Group", "1998"], ["Health related quality of life, cognitive function, and depression in diabetic patients with foot ulcer or amputation. A preliminary study", "2005"], ["Risk factors associated with adverse outcomes in a population\u2010based prospective cohort study of people with their first diabetic foot ulcer", "2007"], ["Diabetic heel ulcers: a major risk factor for lower extremity amputation", "2004"], ["The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study", "1994"], ["Software for data transformation for time\u2010to\u2010event outcomes (alfa version)", "2007"], ["A matched cohort study of the risk of cancer in users of becaplermin", "2011"]], "ex": [["Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds", "2006"], ["Topical autologous platelet\u2010derived growth factors in the treatment of chronic diabetes ulcers", "2000"], ["Recombinant human platelet\u2010derived growth factor\u2010BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open\u2010label clinical evaluation of efficacy", "2000"], ["Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers", "2006"], ["Use of topical recombinant human platelet\u2010derived growth factor\u2010BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers", "1999"], ["Recombinant human epidermal growth factor (REGEN\u2010D 150): effect on healing of diabetic foot ulcers", "2007"], ["Platelet\u2010rich plasma versus platelet\u2010poor plasma in the management of chronic diabetic foot ulcers: a comparative study", "2011"], ["The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results", "2009"], ["Active post\u2010marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers", "2013"]], "in": [["Efficacy of topical epidermal growth factor in healing diabetic foot ulcers", "2005"], ["Use of a platelet\u2010derived growth factor gel in chronic diabetic foot ulcers", "2009"], ["Which is the better option: recombinant human PDGF\u2010BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off\u2010loaded by a customized contact cast?", "2009"], ["Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot", "2004"], ["The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes", "1998"], ["A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non\u2010healing diabetic foot ulcers", "2006"], ["Intralesional injections of Citoprot\u2010P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation", "2007"], ["Intralesional administration of epidermal growth factor\u2010based formulation (Heberprot\u2010P) in chronic diabetic foot ulcer: treatment up to complete wound closure", "2009"], ["Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers", "2008"], ["Efficacy of recombinant human platelet\u2010derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double\u2010blind, placebo\u2010controlled study in India", "2005"], ["A randomised controlled dose response trial of activated platelet supernatant, topical CT\u2010102 in chronic, non healing diabetic wounds", "1993"], ["Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers", "2010"], ["Synergistic action of protease\u2010modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial", "2007"], ["Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture\u2010controlling smart dressing: a randomized, multicenter, prospective analysis", "2010"], ["Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study", "2007"], ["Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers", "2005"], ["Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double\u2010blind, placebo\u2010controlled study", "1995"], ["Effects of transforming growth factor +\u01922 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose\u2010ranging trial", "2002"], ["A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers", "2004"], ["Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT\u2010102 activated platelet supernatant, topical versus placebo", "1992"], ["Clinical evaluation of recombinant human platelet\u2010derived growth factor for the treatment of lower extremity ulcers", "2006"], ["Promotion and acceleration of diabetic ulcer healing by arginine glycine\u2010aspartic acid (RGD) peptide matrix", "1995"], ["Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets", "1996"], ["Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients", "2008"], ["Human epidermal growth factor enhances healing of diabetic foot ulcers", "2003"], ["Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer", "2009"], ["A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN\u2010D 150) in healing diabetic foot ulcers", "2006"], ["Efficacy and safety of a topical gel formulation of recombinant human platelet\u2010derived growth factor\u2010BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo\u2010controlled double\u2010blind study", "1998"]]}